THE 60-SECOND GUIDE
Selank
Controlled human evidence.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Selank is an experimental peptide studied for anxiety-related effects. Its clinical record includes a small Russian comparison with the anxiolytic medazepam. A measured change in anxiety symptoms within such a study is different from establishing broad effectiveness or dependable long-term safety. [1]
Potential benefits
Studied for anxiety-related and neurobehavioral effects. Derived from a tuftsin-related peptide concept. [1]
Evidence & its limits
The small active-comparator study does not establish equivalence to standard treatments or the safety of long-term use. FDA identifies potential immune reactions involving aggregation and peptide impurities in compounded Selank acetate and states that important human safety information is lacking. [1]
Risks & unknowns
Not FDA-approved. Evidence outside its regional research tradition remains limited. [1]
Status & scope
Not FDA-approved. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- Small comparative study in anxiety disorders, 2008
- FDA compounding safety concerns
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.